Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant HPV Vaccination and Screening in Sweden
NCT04910802Phase 4Recruiting
- Start
- May 2021
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and Cervical Cancer (CC). Primary endpoint: Prevalence of HPV at 6 years. Started May 2021; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT04910802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910802.